"Most biotechnology companies have high R&D expenses. There is nothing trivial about that unless this is the first biotech stock you've invested in and are not accustomed to the industry."
I was not referring to the expenses. I was referring to the time.
"No matter how you look at it, 8 years is not the definition of instant gratification."
Again, the point I'm trying to make is the time involved and the transformation from mostly R&D to pushing the product out. This new technology has not been "for sale" to the masses for 8 years.
"The company makes press releases available that state "an independent analyst has projected Nanologix to produce $900,000 in revenue for 2014". I didn't put that information out, Nanologix did. So when you see something like that and take note of how enthusiastic the investors are over news like that, and then you look at the actual financial statement that says $18,550 in revenue, and this kind of situation happens over and over again, you start to realize that something isn't right here."
I believe the press release was put out in January? Are those numbers supposed to be factored into the Q1 results? Now, whether you believe the 900K deal or not, it's up to you on how to move forward with the company. You can't expect this 900K to show up in Q1, heck, the agreement was signed on Jan-9-14. Was Nasaem Al-Jazira supposed to cut Bret a check for 900K at that point? That’s ridiculous. In my opinion, more of the story will become evident with the release of Q2, Q3, and Q4.
News 
Market Data 
Discover 
